These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 19834617)

  • 21. Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains.
    Jowaed A; Schmitt I; Kaut O; Wüllner U
    J Neurosci; 2010 May; 30(18):6355-9. PubMed ID: 20445061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced expression of α-synuclein in alcoholic brain: influence of SNCA-Rep1 genotype.
    Janeczek P; MacKay RK; Lea RA; Dodd PR; Lewohl JM
    Addict Biol; 2014 May; 19(3):509-15. PubMed ID: 22974310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HSP90 and Its Novel Co-Chaperones, SGT1 and CHP-1, in Brain of Patients with Parkinson's Disease and Dementia with Lewy Bodies.
    Bohush A; Niewiadomska G; Weis S; Filipek A
    J Parkinsons Dis; 2019; 9(1):97-107. PubMed ID: 30741686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease.
    Mizuta I; Satake W; Nakabayashi Y; Ito C; Suzuki S; Momose Y; Nagai Y; Oka A; Inoko H; Fukae J; Saito Y; Sawabe M; Murayama S; Yamamoto M; Hattori N; Murata M; Toda T
    Hum Mol Genet; 2006 Apr; 15(7):1151-8. PubMed ID: 16500997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration.
    Zharikov A; Bai Q; De Miranda BR; Van Laar A; Greenamyre JT; Burton EA
    Neurobiol Dis; 2019 May; 125():146-153. PubMed ID: 30658149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calbindin 1, fibroblast growth factor 20, and alpha-synuclein in sporadic Parkinson's disease.
    Mizuta I; Tsunoda T; Satake W; Nakabayashi Y; Watanabe M; Takeda A; Hasegawa K; Nakashima K; Yamamoto M; Hattori N; Murata M; Toda T
    Hum Genet; 2008 Aug; 124(1):89-94. PubMed ID: 18568448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does α-synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease?
    Markopoulou K; Biernacka JM; Armasu SM; Anderson KJ; Ahlskog JE; Chase BA; Chung SJ; Cunningham JM; Farrer M; Frigerio R; Maraganore DM
    Parkinsonism Relat Disord; 2014 Jun; 20(6):584-9; discussion 584. PubMed ID: 24656894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. alpha-Synuclein and Parkinson disease susceptibility.
    Winkler S; Hagenah J; Lincoln S; Heckman M; Haugarvoll K; Lohmann-Hedrich K; Kostic V; Farrer M; Klein C
    Neurology; 2007 Oct; 69(18):1745-50. PubMed ID: 17872362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease.
    Linnertz C; Lutz MW; Ervin JF; Allen J; Miller NR; Welsh-Bohmer KA; Roses AD; Chiba-Falek O
    Hum Mol Genet; 2014 Sep; 23(18):4814-21. PubMed ID: 24777780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease.
    Gründemann J; Schlaudraff F; Haeckel O; Liss B
    Nucleic Acids Res; 2008 Apr; 36(7):e38. PubMed ID: 18332041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease.
    Maraganore DM; de Andrade M; Elbaz A; Farrer MJ; Ioannidis JP; Krüger R; Rocca WA; Schneider NK; Lesnick TG; Lincoln SJ; Hulihan MM; Aasly JO; Ashizawa T; Chartier-Harlin MC; Checkoway H; Ferrarese C; Hadjigeorgiou G; Hattori N; Kawakami H; Lambert JC; Lynch T; Mellick GD; Papapetropoulos S; Parsian A; Quattrone A; Riess O; Tan EK; Van Broeckhoven C;
    JAMA; 2006 Aug; 296(6):661-70. PubMed ID: 16896109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SNCA variants and alpha-synuclein level in CD45+ blood cells in Parkinson's disease.
    Emelyanov A; Kulabukhova D; Garaeva L; Senkevich K; Verbitskaya E; Nikolaev M; Andoskin P; Kopytova A; Milyukhina I; Yakimovskii A; Timofeeva A; Prakhova L; Ilves A; Vlasova I; Pchelina S
    J Neurol Sci; 2018 Dec; 395():135-140. PubMed ID: 30316070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication.
    Flierl A; Oliveira LM; Falomir-Lockhart LJ; Mak SK; Hesley J; Soldner F; Arndt-Jovin DJ; Jaenisch R; Langston JW; Jovin TM; Schüle B
    PLoS One; 2014; 9(11):e112413. PubMed ID: 25390032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of alpha-synuclein expression in alcohol-preferring and -non preferring rats.
    Liang T; Carr LG
    J Neurochem; 2006 Oct; 99(2):470-82. PubMed ID: 17029600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variants in the 3'UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression.
    Schmitt I; Wüllner U; van Rooyen JP; Khazneh H; Becker J; Volk A; Kubisch C; Becker T; Kostic VS; Klein C; Ramirez A
    Eur J Hum Genet; 2012 Dec; 20(12):1265-9. PubMed ID: 22617348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson's disease.
    Uehara T; Choong CJ; Nakamori M; Hayakawa H; Nishiyama K; Kasahara Y; Baba K; Nagata T; Yokota T; Tsuda H; Obika S; Mochizuki H
    Sci Rep; 2019 May; 9(1):7567. PubMed ID: 31110191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population.
    Myhre R; Toft M; Kachergus J; Hulihan MM; Aasly JO; Klungland H; Farrer MJ
    Acta Neurol Scand; 2008 Nov; 118(5):320-7. PubMed ID: 18485051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of risk factor variants of LRRK2, MAPT, SNCA and TCEANC2 genes in Hungarian sporadic Parkinson's disease patients.
    Boros FA; Török R; Vágvölgyi-Sümegi E; Pesei ZG; Klivényi P; Vécsei L
    Neurosci Lett; 2019 Jul; 706():140-145. PubMed ID: 31085292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease.
    Mellick GD; Maraganore DM; Silburn PA
    Neurosci Lett; 2005 Feb; 375(2):112-6. PubMed ID: 15670652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SNCA REP1 and Parkinson's disease.
    Shu L; Zhang Y; Sun Q; Pan H; Guo J; Tang B
    Neurosci Lett; 2018 Aug; 682():79-84. PubMed ID: 29859327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.